Mersana's strategic restructuring and reprioritization plan will reduce the company's workforce by approximately 55% across functions. The workforce reduction is expected to be substantially complete by the end of the third quarter of 2025. "We continue to believe that Emi-Le's differentiated profile offers an opportunity to meaningfully benefit patients," said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics. "Given today's increasingly challenging macro-economic conditions ...